Geneva, Switzerland, November1,2021 – Therapeutic Addex (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering the discovery and development of drugs based on allosteric modulation, today announced that it will release its third quarter 2021 financial results on Thursday 4 November 2021. Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business update and review its pipeline in a conference call and webcast for investors, analysts and media at 4:00 p.m. CET (3:00 p.m. GMT / 11:00 a.m. EDT / 8:00 a.m. PDT) on the same day.
Title: Addex Therapeutics to Report Third Quarter Financial Results and Company Update
Date: November 4, 2021
Time: 4:00 p.m. CET (3:00 p.m. GMT / 11:00 a.m. EDT / 8:00 a.m. PDT)
Join the conference call:
1: Within 10 minutes before the start time of the call, call the call number of the participant.
- Switzerland +41 44 580 65 22
- United Kingdom +44 20 30 09 24 70
- United States +1 87 74 23 08 30
- Other countries
2: Provide the Operator with the Participation pinCoded: 89492779 #
About Addex Therapeutics:
AddexTherapeutic is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of new orally available small molecule drugs called allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional “orthosteric” small molecules or biologics. Addex’s allosteric modulator drug discovery platform targets receptors and other proteins recognized as essential for therapeutic intervention. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator, or NAM), is in a pivotal registration clinical trial for levodopa-induced dyskinesia (PD-LID) in Parkinson’s disease and entered a Phase 2 clinical study for the treatment of blepharospasm, a form of dystonia. Addex’s third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a phase 2a proof-of-concept clinical trial for the treatment of epilepsy. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates focusing on addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex shares are listed on the SIX Swiss Exchange and the American Depositary Shares representing its shares are listed on the NASDAQ Capital Market and trade under the symbol “ADXN” on each stock exchange.
Addex Forward-looking statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, in particular with regard to the early initiation of clinical trials. The words “may”, “will”, “could”, “should”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, ” estimate “,” predict “,” project “,” potential “,” continue “,” target “and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All forward-looking statements contained in this press release are based on the current expectations and beliefs of management and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to occur. differ materially from those expressed or implied by any forward-looking statement. the forward-looking statements contained in this press release, including, without limitation, uncertainties relating to market conditions. These and other risks and uncertainties are described in the Company’s annual report on Form 20-F filed with the SEC on March 11, 2021, as well as in market conditions and regulatory review. All forward-looking statements contained in this press release represent the views of Addex Therapeutics only as of the date hereof and should not be taken as representing its views as of any later date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.